跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SOS1 inhibitor (cancer)
首页
药物
SOS1 inhibitor (cancer)
SOS1 inhibitor (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Anti-cancer combination therapy comprising SOS1 inhibitor and KRAS G12C inhibitor
申请人: BOEHRINGER INGELHEIM INT
优先权: 2020
CN
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG
申请人: KANAPH THERAPEUTICS INC
优先权: 2023
CN
EP
WO
3 件公开
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SOS1 INHIBITOR AND KRAS INHIBITOR
申请人: JEIL PHARMACEUTICAL CO LTD
优先权: 2024
WO
COMBINATION OF ZONGERTINIB WITH A SOS1 INHIBITOR FOR USE IN THE TREATMENT OF CANCER
申请人: BOEHRINGER INGELHEIM INT
优先权: 2024
WO
ANTICANCER THERAPY
申请人: BOEHRINGER INGELHEIM INT
优先权: 2021
CN
EP
US
WO
4 件公开
SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure
申请人: HAIHE BIOPHARMA CO LTD
优先权: 2021
CN
US
2 件公开
NITROGEN-CONTAINING FUNCTIONAL GROUP-SUBSTITUTED PYRIDAZINOPYRIDONE DERIVATIVE AND USE THEREOF
申请人: SICHUAN HUIYU PHARMACEUTICAL CO LTD
优先权: 2023
EP
WO
2 件公开
METHOD FOR HIGH-THROUGHPUT SCREENING OF ANTI-GASTRIC CANCER DRUGS
申请人: ZHEJIANG CANCER HOSPITAL
优先权: 2024
CN
WO
2 件公开
药物
反馈